Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Neurologia i Neurochirurgia Polska
MENU
Shortcuts Submit an article Guide for Authors Special collections Ahead Of Print Reviewers 2023

open access

Vol 55, No 5 (2021)
Review Article
Submitted: 2021-05-17
Accepted: 2021-06-02
Published online: 2021-09-20
View PDF Download PDF file
Get Citation

Vigabatrin — new data on indications and safety in paediatric epilepsy

Weronika Golec1, Elżbieta Sołowiej1, Jolanta Strzelecka1, Elżbieta Jurkiewicz2, Sergiusz Jóźwiak1
DOI: 10.5603/PJNNS.a2021.0063
·
Pubmed: 34541635
·
Neurol Neurochir Pol 2021;55(5):429-439.
Affiliations
  1. Department of Child Neurology, Medical University of Warsaw, Poland
  2. Department of Diagnostic Imaging, The Children’s Memorial Health Institute, Warsaw, Poland

open access

Vol 55, No 5 (2021)
Review articles
Submitted: 2021-05-17
Accepted: 2021-06-02
Published online: 2021-09-20

Abstract

Introduction: Vigabatrin (VGB), a second-generation antiepileptic drug, is effective for the treatment of infantile spasms and focal seizures, primarily in tuberous sclerosis complex (TSC) patients. However, reports of adverse events of VGB, including VGB-associated visual field loss and brain abnormalities in neuroimaging, have raised concerns about the broader use of VGB and thus significantly limited its application.

Aim of the study: The goal of this review was to summarise the recent therapeutic guidelines, the use of VGB in focal seizures and new VGB applications as a disease-modifying treatment in TSC patients. Moreover, we discuss the current opinions on potential VGB-associated toxicity and the safety of VGB.

Abstract

Introduction: Vigabatrin (VGB), a second-generation antiepileptic drug, is effective for the treatment of infantile spasms and focal seizures, primarily in tuberous sclerosis complex (TSC) patients. However, reports of adverse events of VGB, including VGB-associated visual field loss and brain abnormalities in neuroimaging, have raised concerns about the broader use of VGB and thus significantly limited its application.

Aim of the study: The goal of this review was to summarise the recent therapeutic guidelines, the use of VGB in focal seizures and new VGB applications as a disease-modifying treatment in TSC patients. Moreover, we discuss the current opinions on potential VGB-associated toxicity and the safety of VGB.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

vigabatrin, infantile spasms, focal seizures, tuberous sclerosis complex, preventive treatment, VGB-associated visual field loss, VGB-associated brain abnormalities

About this article
Title

Vigabatrin — new data on indications and safety in paediatric epilepsy

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 55, No 5 (2021)

Article type

Review Article

Pages

429-439

Published online

2021-09-20

Page views

7837

Article views/downloads

2070

DOI

10.5603/PJNNS.a2021.0063

Pubmed

34541635

Bibliographic record

Neurol Neurochir Pol 2021;55(5):429-439.

Keywords

vigabatrin
infantile spasms
focal seizures
tuberous sclerosis complex
preventive treatment
VGB-associated visual field loss
VGB-associated brain abnormalities

Authors

Weronika Golec
Elżbieta Sołowiej
Jolanta Strzelecka
Elżbieta Jurkiewicz
Sergiusz Jóźwiak

References (91)
  1. Ben-Menachem E. Mechanism of action of vigabatrin: correcting misperceptions. Acta Neurol Scand Suppl. 2011(192): 5–15.
    CrossRefPubMed
  2. Yang J, Shen J. Elevated endogenous GABA concentration attenuates glutamate-glutamine cycling between neurons and astroglia. J Neural Transm (Vienna). 2009; 116(3): 291–300.
    CrossRefPubMed
  3. Iannetti P, Spalice A, Perla FM, et al. Visual field constriction in children with epilepsy on vigabatrin treatment. Pediatrics. 2000; 106(4): 838–842.
    CrossRefPubMed
  4. Wohlrab G, Boltshauser E, Schmitt B, et al. Visual field constriction is not limited to children treated with vigabatrin. Neuropediatrics. 1999; 30(3): 130–132.
    CrossRefPubMed
  5. Elterman RD, Shields WD, Bittman RM, et al. Vigabatrin for the treatment of infantile spasms: final report of a randomized trial. J Child Neurol. 2010; 25(11): 1340–1347.
    CrossRefPubMed
  6. European Medicines Agency. Opinion of the committee for proprietary medicinal products pursuant to article 12 of council directive 75/319/EEC as amended, for vigabatrin. 1999.
  7. Specchio N, Pietrafusa N, Ferretti A, et al. Treatment of infantile spasms: why do we know so little? Expert Rev Neurother. 2020; 20(6): 551–566.
    CrossRefPubMed
  8. van der Poest Clement E, Jansen FE, Braun KPJ, et al. Update on Drug Management of Refractory Epilepsy in Tuberous Sclerosis Complex. Paediatr Drugs. 2020; 22(1): 73–84.
    CrossRefPubMed
  9. Sabril [package insert]. Deerfield, IL: Lundbeck LLC; 2013. n.d.
  10. Hancock E, Osborne JP. Vigabatrin in the treatment of infantile spasms in tuberous sclerosis: literature review. J Child Neurol. 1999; 14(2): 71–74.
    CrossRefPubMed
  11. Klein P, Friedman A, Hameed MQ, et al. Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy? Epilepsia. 2020; 61(3): 359–386.
    CrossRefPubMed
  12. Zhang Bo, McDaniel SS, Rensing NR, et al. Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex. PLoS One. 2013; 8(2): e57445.
    CrossRefPubMed
  13. Wilmshurst JoM, Gaillard WD, Vinayan KP, et al. Summary of recommendations for the management of infantile seizures: Task Force Report for the ILAE Commission of Pediatrics. Epilepsia. 2015; 56(8): 1185–1197.
    CrossRefPubMed
  14. Thodeson D, Sogawa Y. Practice experience in the treatment of infantile spasms at a tertiary care center. Pediatr Neurol. 2014; 51(5): 696–700.
    CrossRefPubMed
  15. Friedman D, Bogner M, Parker-Menzer K, et al. Vigabatrin for partial-onset seizure treatment in patients with tuberous sclerosis complex. Epilepsy Behav. 2013; 27(1): 118–120.
    CrossRefPubMed
  16. Greiner HM, Lynch ER, Fordyce S, et al. Vigabatrin for childhood partial-onset epilepsies. Pediatr Neurol. 2012; 46(2): 83–88.
    CrossRefPubMed
  17. Nabbout RC, Chiron C, Mumford J, et al. Vigabatrin in partial seizures in children. J Child Neurol. 1997; 12(3): 172–177.
    CrossRefPubMed
  18. Jackson MC, Jafarpour S, Klehm J, et al. Effect of vigabatrin on seizure control and safety profile in different subgroups of children with epilepsy. Epilepsia. 2017; 58(9): 1575–1585.
    CrossRefPubMed
  19. Jia JL, Chen S, Sivarajah V, et al. Latitudinal differences on the global epidemiology of infantile spasms: systematic review and meta-analysis. Orphanet J Rare Dis. 2018; 13(1): 216.
    CrossRefPubMed
  20. Talwar D, Baldwin MA, Hutzler R, et al. Epileptic spasms in older children: persistence beyond infancy. Epilepsia. 1995; 36(2): 151–155.
    CrossRefPubMed
  21. Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017; 58(4): 512–521.
    CrossRefPubMed
  22. Messer R, Knupp KG. Infantile Spasms: Opportunities to Improve Care. Semin Neurol. 2020; 40(2): 236–245.
    CrossRefPubMed
  23. Elterman RD, Shields WD, Bittman RM, et al. US Infantile Spasms Vigabatrin Study Group. Randomized trial of vigabatrin in patients with infantile spasms. Neurology. 2001; 57(8): 1416–1421.
    CrossRefPubMed
  24. Primec ZR, Stare J, Neubauer D. The risk of lower mental outcome in infantile spasms increases after three weeks of hypsarrhythmia duration. Epilepsia. 2006; 47(12): 2202–2205.
    CrossRefPubMed
  25. Widjaja E, Go C, McCoy B, et al. Neurodevelopmental outcome of infantile spasms: A systematic review and meta-analysis. Epilepsy Res. 2015; 109: 155–162.
    CrossRefPubMed
  26. O'Callaghan FJK, Lux AL, Darke K, et al. The effect of lead time to treatment and of age of onset on developmental outcome at 4 years in infantile spasms: evidence from the United Kingdom Infantile Spasms Study. Epilepsia. 2011; 52(7): 1359–1364.
    CrossRefPubMed
  27. Darke K, Edwards SW, Hancock E, et al. trial steering committee on behalf of participating investigators, United Kingdom Infantile Spasms Study. The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. Lancet. 2004; 364(9447): 1773–1778.
    CrossRefPubMed
  28. Lux AL, Edwards SW, Hancock E, et al. United Kingdom Infantile Spasms Study. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. Lancet Neurol. 2005; 4(11): 712–717.
    CrossRefPubMed
  29. Djuric M, Kravljanac R, Tadic B, et al. Long-term outcome in children with infantile spasms treated with vigabatrin: a cohort of 180 patients. Epilepsia. 2014; 55(12): 1918–1925.
    CrossRefPubMed
  30. Darke K, Edwards SW, Hancock E, et al. trial steering committee on behalf of participating investigators. Developmental and epilepsy outcomes at age 4 years in the UKISS trial comparing hormonal treatments to vigabatrin for infantile spasms: a multi-centre randomised trial. Arch Dis Child. 2010; 95(5): 382–386.
    CrossRefPubMed
  31. Knupp KG, Coryell J, Nickels KC, et al. Pediatric Epilepsy Research Consortium. Response to treatment in a prospective national infantile spasms cohort. Ann Neurol. 2016; 79(3): 475–484.
    CrossRefPubMed
  32. O'Callaghan FJK, Edwards SW, Alber FD, et al. participating investigators. Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial. Lancet Neurol. 2017; 16(1): 33–42.
    CrossRefPubMed
  33. O'Callaghan FJK, Edwards SW, Alber FD, et al. International Collaborative Infantile Spasms Study (ICISS) investigators. Vigabatrin with hormonal treatment versus hormonal treatment alone (ICISS) for infantile spasms: 18-month outcomes of an open-label, randomised controlled trial. Lancet Child Adolesc Health. 2018; 2(10): 715–725.
    CrossRefPubMed
  34. Hahn J, Park G, Kang HC, et al. Optimized treatment for infantile spasms: Vigabatrin versus Prednisolone versus combination therapy. J Clin Med. 2019; 8(10).
    CrossRefPubMed
  35. Camposano SE, Major P, Halpern E, et al. Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile. Epilepsia. 2008; 49(7): 1186–1191.
    CrossRefPubMed
  36. Bresnahan R, Gianatsi M, Maguire MJ, et al. Vigabatrin add-on therapy for drug-resistant focal epilepsy. Cochrane Database Syst Rev. 2020; 7: CD007302.
    CrossRefPubMed
  37. Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. The Lancet. 2008; 372(9639): 657–668.
    CrossRef
  38. Stafstrom CE, Staedtke V, Comi AM. Epilepsy mechanisms in neurocutaneous disorders: tuberous sclerosis complex, neurofibromatosis type 1, and Sturge-Weber syndrome. Front Neurol. 2017; 8: 87.
    CrossRefPubMed
  39. Curatolo P, Nabbout R, Lagae L, et al. Management of epilepsy associated with tuberous sclerosis complex: Updated clinical recommendations. Eur J Paediatr Neurol. 2018; 22(5): 738–748.
    CrossRefPubMed
  40. Overwater IE, Bindels-de Heus K, Rietman AB, et al. Epilepsy in children with tuberous sclerosis complex: Chance of remission and response to antiepileptic drugs. Epilepsia. 2015; 56(8): 1239–1245.
    CrossRefPubMed
  41. Chu-Shore CJ, Major P, Camposano S, et al. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia. 2010; 51(7): 1236–1241.
    CrossRefPubMed
  42. Kingswood JC, Belousova E, Benedik MP, et al. TOSCA Consortium and TOSCA Investigators. Epilepsy in tuberous sclerosis complex: Findings from the TOSCA study. Epilepsia Open. 2019; 4(1): 73–84.
    CrossRefPubMed
  43. Krueger DA, Northrup H, Northrup H, et al. International Tuberous Sclerosis Complex Consensus Group, International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013; 49(4): 243–254.
    CrossRefPubMed
  44. Yum MS, Lee EH, Ko TS. Vigabatrin and mental retardation in tuberous sclerosis: infantile spasms versus focal seizures. J Child Neurol. 2013; 28(3): 308–313.
    CrossRefPubMed
  45. Jóźwiak S, Kotulska K, Domańska-Pakieła D, et al. Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex. Eur J Paediatr Neurol. 2011; 15(5): 424–431.
    CrossRefPubMed
  46. Bombardieri R, Pinci M, Moavero R, et al. Early control of seizures improves long-term outcome in children with tuberous sclerosis complex. Eur J Paediatr Neurol. 2010; 14(2): 146–149.
    CrossRefPubMed
  47. Cusmai R, Moavero R, Bombardieri R, et al. Long-term neurological outcome in children with early-onset epilepsy associated with tuberous sclerosis. Epilepsy Behav. 2011; 22(4): 735–739.
    CrossRefPubMed
  48. Riikonen RS. Favourable prognostic factors with infantile spasms. Eur J Paediatr Neurol. 2010; 14(1): 13–18.
    CrossRefPubMed
  49. Hussain SA, Schmid E, Peters JM, et al. Tuberous Sclerosis Complex Autism Center of Excellence Network. High vigabatrin dosage is associated with lower risk of infantile spasms relapse among children with tuberous sclerosis complex. Epilepsy Res. 2018; 148: 1–7.
    CrossRefPubMed
  50. Galanopoulou AS, Gorter JA, Cepeda C. Finding a better drug for epilepsy: the mTOR pathway as an antiepileptogenic target. Epilepsia. 2012; 53(7): 1119–1130.
    CrossRefPubMed
  51. Słowińska M, Jóźwiak S, Peron A, et al. Early diagnosis of tuberous sclerosis complex: a race against time. How to make the diagnosis before seizures? Orphanet J Rare Dis. 2018; 13(1): 25.
    CrossRefPubMed
  52. Słowińska M, Golec W, Jóźwiak S. Prevention of epilepsy in humans - truth or myth? The experience from Sturge-Weber syndrome and Tuberous Sclerosis Complex. Neurol Neurochir Pol. 2019; 53(3): 190–193.
    CrossRefPubMed
  53. Jozwiak S, Słowińska M, Borkowska J, et al. Preventive antiepileptic treatment in tuberous sclerosis complex: A long-term, prospective trial. Pediatr Neurol. 2019; 101: 18–25.
    CrossRefPubMed
  54. Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex - Full Text View - ClinicalTrials.gov n.d. https://clinicaltrials.gov/ct2/show/NCT02849457 (February 21, 2021).
  55. Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis Complex - Full Text View - ClinicalTrials.gov n.d. https://clinicaltrials.gov/ct2/show/NCT02098759 (February 21, 2021).
  56. Kotulska K, Kwiatkowski DJ, Curatolo P, et al. EPISTOP Investigators. Prevention of epilepsy in infants with tuberous sclerosis complex in the EPISTOP trial. Ann Neurol. 2021; 89(2): 304–314.
    CrossRefPubMed
  57. Carmant L. Vigabatrin therapy for infantile spasms: review of major trials in Europe, Canada, and the United States; and recommendations for dosing. Acta Neurol Scand Suppl. 2011(192): 36–47.
    CrossRefPubMed
  58. Moavero R, Pisani LR, Pisani F, et al. Safety and tolerability profile of new antiepileptic drug treatment in children with epilepsy. Expert Opin Drug Saf. 2018; 17(10): 1015–1028.
    CrossRefPubMed
  59. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ. 1997; 314(7075): 180–181.
    CrossRefPubMed
  60. Krauss GL, Johnson MA, Miller NR. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology. 1998; 50(3): 614–618.
    CrossRefPubMed
  61. Vanhatalo S, Pääkkönen L, Nousiainen I. Visual field constriction in children treated with vigabatrin. Neurology. 1999; 52(8): 1713–1714.
    CrossRefPubMed
  62. Vanhatalo S, Nousiainen I, Eriksson K, et al. Visual field constriction in 91 Finnish children treated with vigabatrin. Epilepsia. 2002; 43(7): 748–756.
    CrossRefPubMed
  63. Maguire MJ, Hemming K, Wild JM, et al. Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review. Epilepsia. 2010; 51(12): 2423–2431.
    CrossRefPubMed
  64. Gaily E, Jonsson H, Lappi M. Visual fields at school-age in children treated with vigabatrin in infancy. Epilepsia. 2009; 50(2): 206–216.
    CrossRefPubMed
  65. Wohlrab G, Leiba H, Kästle R, et al. Vigabatrin therapy in infantile spasms: solving one problem and inducing another? Epilepsia. 2009; 50(8): 2006–2008.
    CrossRefPubMed
  66. Westall CA, Wright T, Cortese F, et al. Vigabatrin retinal toxicity in children with infantile spasms: An observational cohort study. Neurology. 2014; 83(24): 2262–2268.
    CrossRefPubMed
  67. Moskowitz A, Hansen RM, Eklund SE, et al. Electroretinographic (ERG) responses in pediatric patients using vigabatrin. Doc Ophthalmol. 2012; 124(3): 197–209.
    CrossRefPubMed
  68. Moseng L, Sæter M, Mørch-Johnsen GH, et al. Retinal nerve fibre layer attenuation: clinical indicator for vigabatrin toxicity. Acta Ophthalmol. 2011; 89(5): 452–458.
    CrossRefPubMed
  69. Nousiainen I, Mäntyjärvi M, Kälviäinen R. No reversion in vigabatrin-associated visual field defects. Neurology. 2001; 57(10): 1916–1917.
    CrossRefPubMed
  70. Chiron C, Dulac O. Epilepsy: Vigabatrin treatment and visual field loss. Nat Rev Neurol. 2011; 7(4): 189–190.
    CrossRefPubMed
  71. Hardus P, Verduin WM, Engelsman M, et al. Visual field loss associated with vigabatrin: quantification and relation to dosage. Epilepsia. 2001; 42(2): 262–267.
    CrossRefPubMed
  72. Wild JM, Chiron C, Ahn H, et al. Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: final results from an open-label, observational, multicentre study. CNS Drugs. 2009; 23(11): 965–982.
    CrossRefPubMed
  73. Sergott R, Wheless J, Smith M, et al. Evidence-based review of recommendations for visual function testing in patients treated with vigabatrin. Neuro-Ophthalmology. 2010; 34(1): 20–35.
    CrossRef
  74. Pellock JM, Faught E, Foroozan R, et al. Which children receive vigabatrin? Characteristics of pediatric patients enrolled in the mandatory FDA registry. Epilepsy Behav. 2016; 60: 174–180.
    CrossRefPubMed
  75. Krauss G, Faught E, Foroozan R, et al. Sabril® registry 5-year results: Characteristics of adult patients treated with vigabatrin. Epilepsy Behav. 2016; 56: 15–19.
    CrossRefPubMed
  76. Foroozan R. Vigabatrin: lessons learned from the United States experience. J Neuroophthalmol. 2018; 38(4): 442–450.
    CrossRefPubMed
  77. Sergott RC, Johnson CA, Laxer KD, et al. Retinal structure and function in vigabatrin-treated adult patients with refractory complex partial seizures. Epilepsia. 2016; 57(10): 1634–1642.
    CrossRefPubMed
  78. Plant GT, Sergott RC. Understanding and interpreting vision safety issues with vigabatrin therapy. Acta Neurol Scand Suppl. 2011(192): 57–71.
    CrossRefPubMed
  79. Balestrini S, Clayton LMS, Bartmann AP, et al. Retinal nerve fibre layer thinning is associated with drug resistance in epilepsy. J Neurol Neurosurg Psychiatry. 2016; 87(4): 396–401.
    CrossRefPubMed
  80. Schwarz MD, Li M, Tsao J, et al. A lack of clinically apparent vision loss among patients treated with vigabatrin with infantile spasms: The UCLA experience. Epilepsy Behav. 2016; 57(Pt A): 29–33.
    CrossRefPubMed
  81. McFarlane MT, Wright T, McCoy B, et al. Retinal defect in children with infantile spasms of varying etiologies: An observational study. Neurology. 2020; 94(6): e575–e582.
    CrossRefPubMed
  82. Dracopoulos A, Widjaja E, Raybaud C, et al. Vigabatrin-associated reversible MRI signal changes in patients with infantile spasms. Epilepsia. 2010; 51(7): 1297–1304.
    CrossRefPubMed
  83. Wheless JW, Carmant L, Bebin M, et al. Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy. Epilepsia. 2009; 50(2): 195–205.
    CrossRefPubMed
  84. Simao GN, Zarei Mahmoodabadi S, Snead OC, et al. Abnormal axial diffusivity in the deep gray nuclei and dorsal brain stem in infantile spasm treated with vigabatrin. AJNR Am J Neuroradiol. 2011; 32(1): 199–203.
    CrossRefPubMed
  85. Hussain SA, Tsao J, Li M, et al. Risk of vigabatrin-associated brain abnormalities on MRI in the treatment of infantile spasms is dose-dependent. Epilepsia. 2017; 58(4): 674–682.
    CrossRefPubMed
  86. Pearl PL, Vezina LG, Saneto RP, et al. Cerebral MRI abnormalities associated with vigabatrin therapy. Epilepsia. 2009; 50(2): 184–194.
    CrossRefPubMed
  87. Dill P, Datta AN, Weber P, et al. Are vigabatrin induced T2 hyperintensities in cranial MRI associated with acute encephalopathy and extrapyramidal symptoms? Eur J Paediatr Neurol. 2013; 17(3): 311–315.
    CrossRefPubMed
  88. Hernández Vega Y, Kaliakatsos M, U-King-Im JM, et al. Reversible vigabatrin-induced life-threatening encephalopathy. JAMA Neurol. 2014; 71(1): 108–109.
    CrossRefPubMed
  89. Fong CYi, Osborne JP, Edwards SW, et al. An investigation into the relationship between vigabatrin, movement disorders, and brain magnetic resonance imaging abnormalities in children with infantile spasms. Dev Med Child Neurol. 2013; 55(9): 862–867.
    CrossRefPubMed
  90. Lotan E, Bluvstein J, Zan E. Vigabatrin toxicity in a patient with infantile spasms treated with concomitant hormonal therapy. Isr Med Assoc J. 2020; 22(7): 461–462.
  91. A Novel Approach to Infantile Spasms - Full Text View - ClinicalTrials.gov n.d. https://clinicaltrials.gov/ct2/show/NCT03347526 (February 21, 2021).

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl